News

News | January 3, 2019

Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809

Read More

News | December 18, 2018

Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita

Read More

News | November 27, 2018

Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

Read More

News | November 20, 2018

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

Read More

News | November 5, 2018

Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering

Read More

News | June 27, 2018

Carisma Nabs $53 Million Series A for Cellular Cancer Therapy

Read More

News | June 26, 2018

Kauffman Fellows Celebrates Its Most Diverse Group of Talented Leaders With Class 23

Read More

News | June 26, 2018

Genome Editing Startup Precision BioSciences Scores $110 Million Series B

Read More

News | June 26, 2018

Skyhawk Therapeutics Gains $100 Million Through Venture Round, Collaboration

Read More

News | June 26, 2018

CAR Macrophage Tumor Tech Created by UPenn Star Scientists Gets $53M

Read More